XOMA Royalty (XOMA) Net Income towards Common Stockholders (2011 - 2026)

XOMA Royalty (XOMA) reported Net Income towards Common Stockholders of $4.5 million for Q1 2026, up 88.64% on a YoY basis from $2.4 million in Q1 2025, and down 51.13% sequentially from $9.1 million in Q4 2025.

XOMA Royalty (XOMA) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends

XOMA Royalty (XOMA) has 16 years of Net Income towards Common Stockholders data on file, last reported at $4.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 88.64% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 104.84% YoY), and the FY2025 full-year result was $31.7 million, up 330.58% from the prior year.
  • Net Income towards Common Stockholders slipped to $4.5 million in Q1 2026, from $9.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $9.1 million in Q4 2025 to a low of -$27.1 million in Q2 2024.
  • A 5-year average of -$10.3 million and a median of -$11.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders tumbled 830.49% in 2022 and surged 195.6% in 2025, its largest moves.
  • Tracing XOMA's Net Income towards Common Stockholders over 5 years: stood at -$6.3 million in 2022, then tumbled by 225.0% to -$20.3 million in 2023, then jumped by 53.03% to -$9.6 million in 2024, then surged by 195.6% to $9.1 million in 2025, then plunged by 51.13% to $4.5 million in 2026.
  • Business Quant data shows XOMA's Net Income towards Common Stockholders at $4.5 million in Q1 2026, $9.1 million in Q4 2025, and -$11.1 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 XOMA Royalty 478.42 Mn 412.34 Mn - 4.47 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.47 Mn
Dec 31, 2025 9.14 Mn
Jun 30, 2025 -11.11 Mn
Mar 31, 2025 2.37 Mn
Dec 31, 2024 -9.56 Mn
Sep 30, 2024 -17.24 Mn
Jun 30, 2024 -27.06 Mn
Mar 31, 2024 -10.78 Mn
Dec 31, 2023 -20.35 Mn
Sep 30, 2023 -12.59 Mn
Jun 30, 2023 -17.39 Mn
Mar 31, 2023 -11.07 Mn
Dec 31, 2022 -6.26 Mn
Sep 30, 2022 -14.66 Mn
Jun 30, 2022 -20.82 Mn
Mar 31, 2022 -2.12 Mn
Dec 31, 2021 29.86 Mn
Sep 30, 2021 -4.44 Mn
Jun 30, 2021 -2.24 Mn
Mar 31, 2021 -7.37 Mn